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Summary of Genetic Clinic Population: 1973-1977 
Year Tota l 
1977 Num- Percent 
C lassifica tion 1973-75 1976 J an-June ber of total 
Dominant 
traits 16 55 40 111 12.2 
Recessive 
traits 46 54 61 161 17.8 
Sex-l inked 
traits 16 II 7 34 3.7 
Chromosomal 
disorders 106 258 49 413 45.6 
Multi factorial 
traits 16 24 10 50 5.5 
Other 
conditions 41 55 42 138 15.2 
TOTAL 241 457 209 907 100.0 
sample included patients with D and E trisomy, the 
cri du chat syndrome, Turner syndrome, Klinefelter 
syndrome, the 4p-syndrome, and a variety of struc-
tural rearrangements. 
Patie.nts classified as having multifactorial dis-
eases included individuals with midline neurologic 
defects, diabetes, uncomplicated cleft lips and/ or pal-
ate, clubfeet, seizures, and certain patients with famil-
ial mental retardation that could not be otherwise 
classified. Patients falling into the other categories 
included individuals with multiple malformations or 
repeated abortions with normal chromosomes and no 
other definite causes, or patients with psychomotor 
retardation of unknown or environmental etiology. 
During the year 1976 (Figure), patients came 
from all parts of the state either to the Genetic Coun-
seling and Amniocentesis Clinics or for diagnostic 
karyotypic analysis. This pattern of referrals is 
largely a result of the central location of the Clinic in 
a large urban area. 
Referrals to Genettc Coooseing Program 
from Virginia's Health C•e Districts, 1976 
Figure-Pattern of referrals to Genetic Counseling Program 
from Virginia's health care district, 1976. 
Population Screening for Genetic Disease 
PETER MAMUNES, M .D., Professor of Pediatrics and of Human Genetics 
Recent advances in genetics and laboratory tech-
niques have raised difficult issues for both the medical 
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and lay communities. The desirability of initiating 
population screening progr.ams is an example of one 
such issue that has engendered considerable con-
fusion concerning its intent-so much so that the 
National Academy of Sciences recently reviewed this 
subject and in 1975 published a book entitled, Ge-
netic Screening-Programs, Principles and Research. 1 
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This presentation will describe the four major forms 
of population screening for genetic disease and, from 
the Virginia experience with some of them, demon-
strate their strengths and shortcomings. 
Most readers are already aware of programs to 
screen for disorders such as hypertension, diabetes, 
cervical cancer, glaucoma, and other diseases. These 
programs were established with the idea that they are 
inexpensive, can be detected by a simple test, and that 
effective treatment is available. The same principles 
apply to the four major types of population screening 
programs for genetic disorders . 
I . Carrier detection. Almost all persons are be-
lieved to carry approximately four lethal or dele-
terious recessive genes; however, their existence is 
usually never known unless the spouse has the same 
gene, in which case there is a one-in-four chance that 
each child will inherit a "double dose" of the abnor-
mal gene and develop the disorder. Fortunately, most 
serious recessive diseases are rare, but there are two-
sickle cell disease and Tay-Sachs disease-which are 
especially prevalent in specific subpopulations and 
for which simple, reliable, and relatively inexpensive 
carrier tests are available. Screening programs for 
detection of heterozygotes (carriers) in both disorders 
have existed in Virginia for at least five years . Else-
where in this issue experience with the Medical Col-
lege of Virginia Sickle Cell Program is described. 
Tay-Sachs disease affects approximately 1 : 4,000 
Ashkenazi Jewish births and is invariably lethal by 
the fourth year because of the abnormal accumula-
tion of a sphingolipid, ganglioside G M 2 , in the cen-
tral nervous system.2 Hexosaminidase A, the enzyme 
which is necessary for the normal degradation of this 
material , is inactive in these patients and is present in 
only approximately 50% of normal activity in the 
serum, white blood cells, and other tissues of carriers. 
Women who are at risk to give birth to such children 
can therefore be identified before pregnancy. If both 
parents are carriers, an amniocentesis performed in 
the second trimester can determine the enzyme status 
of the fetus. If Tay-Sachs disease is found, the parents 
then have the option to terminate the pregnancy to 
avert the birth of an affected child. 
Measurement of the serum enzyme level is not in 
itself technically difficult, but so many factors affect 
its activity (for example, pregnancy, cleanliness of 
test tubes in which blood is collected, the time during 
which the serum remains at room temperature before 
freezing, storage temperature prior to testing, medi-
cations taken by patient) that it is not practical for 
the local physician to forward blood to the testing 
laboratory from patients wishing their carrier status 
determined. Although with special precautions and 
arrangements, testing of remote patients can be done, 
a more desirable procedure is to schedule periodic 
mass community testing at various sites. These mo-
bile screening clinics not only obviate the above-
mentioned difficulties but they offer a better opportu-
nity to ensure that tested individuals have been prop-
erly informed regarding the purpose and possible 
consequence of the testing. Because this concept of 
carrier testing is a new one, the most difficult aspect 
of such screening is to educate the public in the 
importance of voluntary participation . Most people 
will not have heard of the disease, and what is more 
significant they find it difficult to believe that they 
have a 1: 30 chance of being carriers. A second ob-
stacle to successful screening is the lack of funding for 
such programs. After initial equipment cost outlay, 
the cost for the Tay-Sachs test averages $7 .00 ± 
$2.00, depending on the volume of tests, per individ-
ual. The MCV Tay-Sachs Screening Program, oper-
ative since 1972, was fortunate to obtain initial sup-
port from the Virginia State Department of Health 
and local Jewish community organizations so that it 
has been able to offer the test without a fixed charge 
to tested persons . 
As a result of Virginia screening, over 3,700 Jew-
ish persons have been tested at sites in their own cities 
of Richmond, Norfolk, Newport News, Roanoke, 
and Fredericksburg; the metropolitan northern Vir-
ginia cities have used testing sites in southern Mary-
land and Washington, D.C., provided by Johns Hop-
kins Hospital. Over 100 carriers have been identified 
and counseled, but surprisingly no carrier couple has 
thus far been found. A full 25% of all adult Jewish 
people in these cities have been tested. In almost all of 
the more populous United States cities where testing 
has been offered for several years, no more than 5% 
to 10% have appeared for this voluntary test. Clearly, 
a significant educational effort is needed on two 
fronts: to convince governmental agencies of the need 
for appropriate funding for these programs and to 
inform the public regarding the concept of disease 
prevention by carrier detection. Support of these ef-
forts is needed soon, for in the very near future car-
rier detection tests for other more common recessive 
diseases, such as cystic fibrosis, promise to be avail-
able. 
Phenylketonuria (PK U) carrier detection is a 
second test that we currently provide, using a dis-
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criminant function, based on serum amino acid lev-
els, that we have recently developed in our labora-
tory. In this case, since there is no ethnic group in 
which the gene has a high incidence, we offer the test 
to the collateral relatives of all new cases of PK U that 
come to our attention. 
2. Antenatal screening. There is a ~mall but 
clearly definable group of pregnant women , for whom 
screening is indicated because of their substantially 
increased risk of bearing a child with a genetic dis-
order. The Antenatal Testing Program, jointly ad-
ministered by\the Departments of Obstetrics and Gy-
necology, Human Genetics , and Pediatrics, is 
discussed elsewhere in this issue. 
3. Mass neonatal screening. The prototype in 
this level of screening is the Guthrie test to detect 
PK U, an assay performed on a dried blood spot 
obtained in the first week of life. Virginia State law 
established the program in 1966 and made it the joint 
responsibility of the parent and/ or the physician to 
provide that the neonate be screened for this condi-
tion. Since that time, four to five children with PK U 
per year (approximately I: 16,000 births) have been 
discovered and mental retardation averted by main-
taining them on a phenylalanine-restricted diet for 
the first six to seven years of life. The cost for early 
screening and treatment is approximately one tenth 
the cost of special education or institutionalization of 
late-diagnosed, retarded PK U children . 
With the demonstrated success of the PK U 
screening program , many states and foreign countries 
have established screening programs for other dis-
orders using the same blood spots. The grafting of 
these additional programs onto an already-existing 
one and the availability of a machine to handle the 
blood-spotted filter paper have minimized their cost. 
The decision of which additional disorders to screen 
should relate to the following major factors: 
a) frequencyofthedisorder, 
b) severity of the untreated disorder, 
c) simplicity and sensitivity of the test, and 
d) availability of treatment to ameliorate or pre-
vent the disorder. 
Under the above considerations, hypothyroidism (by 
radioimmunoassay of thyroxine), galactosemia (by 
bacterial inhibition assay) , and several amino-
acidopathies including homocystinuria, maple syrup 
urine disease (MSUD), and histidinemia (all also by 
bacterial inhibition assay) qualify .3 Because of its 
frequency ( I : 6,000) and ease of treatment, and the 
severity of the mental retardation that ensues due to 
delayed diagnosis, hypothyroidism warrants immedi-
ate development of screening programs .4•5 Therefore, 
a neonatal hypothyroid screening program in Vir-
gini a is planned for 1978. It is hoped that additional 
programs for galactosemia and other aminoacido-
pathies will also be initiated soon. 
The spectrum of metabolic disorders screened 
can be considerably expanded if the urine of two- to 
three-week old infants is ,aiso tested by various simple 
chromatographic and high-voltage electrophoretic 
techniques . Such a program, using specimens col-
lected on filter paper at home by the parent and 
mailed to the central laboratory performing the 
blood tests, has already been in effect for several 
years in M assachusetts6 and several other states. This 
procedure also serves as a follow-up test to detect 
neonates with false-negative blood results for the 
previously mentioned aminoacidopathies, including 
PKU. 
Except for the PKU program, testing for other 
disorders in Virginia and most other states is and will 
be voluntary. An advisory committee of consumers, 
experts in metabolic disease, geneticists, laboratory 
personnel , clergy, and ethicists is clearly needed to 
serve as an advisory body to determine the propriety 
and mode of administration of these proliferating 
programs. 
4. Urine metabolic screening. While the total in-
cidence of ihborn errors of metabolism is probably 
no greater than I: 5,000, these disorders are more 
often seen in children with mental retardation , sei-
zures, hepatosplenomegaly, recurrent or persistent 
acidosis, failure to thrive, or unusual odor to urine or 
sweat. Where the etiology of any of these conditions 
is unclear, one of the inborn errors of metabolism 
must be considered; therefore, a variety of simple 
tests on a random urine specimen is recommended to 
screen for over 30 such disorders of amino acid, 
mucopolysaccharide, and carbohydrate metabolism.7 
At the pediatric metabolic laboratory the following 
tests are routinely performed weekly on a 20 ml acid-
ified random urine specimen received by mail: a) 
ferric chloride and dinitrophenylhydrazine tests to 
detect the alpha-keto acid excesses found in PKU, 
tyrosinemia , MSUD, and histidinemia; b) silver ni-
troprusside test for homocystinuria; c) Benedict's 
tablet for reducing substances; d) gross turbidity test 
for mucopolysaccharidoses; e) isatin spot test for the 
iminoaciduria of praline or hydroxyproline excess; f) 
nitrosonaphthol test for tyrosinosis; and g) high-volt-
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age separation of all urinary amino acids to detect 
any excesses. Although the yield of newly diagnosed 
inborn errors by this screening program is small, 
those few cases detect~d are important because they 
may le;id to a specific diagnosis that permits a prog-
nosis, a recurrence risk for other family members, 
and counseling about the possibility of treatment or 
prenatal diagnosis for future pregnancies. 
Clearly, genetic screening programs are an im-
portant component of the primary care physician's 
efforts in preventive medicine. Participation in and 
support of these programs is therefore strongly 
urged. 
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The Virginia Sickle Cell Anemia Awareness 
Program (VaSCAP): Education, Screening, 
and Counseling 
FLORENCE N. COOPER AND ROBERT B. SCOTT, M.D., Department of Medicine 
In 1968, a program of screening for sickle trait 
carriers was begun as part of the work of the Hema-
tology Division, Department of j'vtedicine, at the 
Medical College of Virginia. It was felt that sickle cell 
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anemia was more of a public health problem than 
was generally recognized, and in addition to institut-
ipg screening and education programs, data were col-
lected to document the rela tive neglect of the prob-
lem. 
A survey of the Cjty of Richmond was con-
ducted to ascertain the level of awareness among 
